会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • AN IMPROVED PROCESS FOR THE PREPARATION OF ARMODAFINIL
    • 改进ARMODAFINIL的制备方法
    • WO2007103221A3
    • 2008-06-26
    • PCT/US2007005451
    • 2007-03-01
    • TEVA PHARMATEVA PHARMAMOSHKOVITS-KAPTSAN RINATBRAUDE VIVIANACHEN KOBIADLER MIRI
    • MOSHKOVITS-KAPTSAN RINATBRAUDE VIVIANACHEN KOBIADLER MIRI
    • C07B57/00A61K31/192A61P25/00C07C315/06C07C317/44C07C319/24C07C321/20
    • C07C315/06C07B57/00C07B2200/07C07C319/24C07C317/44C07C321/20
    • The invention encompasses processes for preparing intermediates, such as (R)-modafinic acid and its C 1-2 alkyl ester, and the conversion of the intermediates into armodafinil. In particular, the invention concerns: (i) a process for the optical resolution of modafinic acid with (R)-a-naphthylethylamine and its conversion into armodafinil; (ii) (R)-modafinic acid containing less than 2% area by HPLC of (S)-modifinic acid; (iii) a process for the preparation of C 1-2 alkyl ester of (R)-modafinic acid from (R)-modafinic acid by reaction with methanol or ethanol in the presence of at least one acidic reagent and its conversion into armodafinil; (iv) armodafinil with less than 0.5% area by HPLC of (S)-modafinil entantiomer, a pharmaceutical composition containing it and process for the preparation of this composition; (v) armodafinil with less than 0.1% area by HPLC of modafinic acid, a pharmaceutical composition containing it and process for the preparation of this composition; (vi) a process for the reduction of modafinic acid content in armodafjnil by contacting a solution with activated basic or neutral alumina; (vii) armodafinil with less than 0.2% area by HPLC of bis(diphenylmethyl) disulphide (R-MDF-DS), a pharmaceutical composition containing it and process for the preparation of this composition; (viii) a process for the preparation of R-MDF-DS from diphenylmethanethiol acetate; and (ix) a process for the reduction of R-MDF-DS content in armodafinil by suspending it in a C 5-10 hydrocarbon.
    • 本发明包括制备中间体的方法,例如(R) - 莫多卡因酸及其C 1-12烷基酯,以及中间体转化成犰狳。 特别地,本发明涉及:(i)用(R)-α-萘基乙胺及其转化成犰狳的光解析莫多卡因酸的方法; (ⅱ)(S) - 二氢ic酸通过HPLC测定含有小于2%面积的(R) - 莫达卡因酸; (iii)通过与甲醇或乙醇在至少一种酸性的存在下反应制备(R) - 莫丹克酸的(R) - 莫丹克酸的C 1-12烷基酯的方法 试剂及其转化成犰狳; (iv)通过HPLC(S) - 莫达非尼对映异构体的HPLC(含有它的药物组合物)具有小于0.5%面积的犰狳,以及制备该组合物的方法; (v)含有不饱和脂肪酸的药物组合物,含有它的药物组合物的面积小于0.1%的臂多糖,以及制备该组合物的方法; (vi)通过使溶液与活性碱性或中性氧化铝接触来降低犰狳中莫达非酸含量的方法; (vii)含有二(二苯基甲基)二硫化物(R-MDF-DS)的双(二苯基甲基)二硫化物(R-MDF-DS))面积小于0.2%的犰狳,含有该组合物的药物组合物及其制备方法; (viii)从二苯基甲硫醇乙酸酯制备R-MDF-DS的方法; 和(ix)通过将其悬浮在C 5-10烃中来降低含量在犰狳中的R-MDF-DS含量的方法。